Obinutuzumab plus chlorambucil packs 1-2 punch against CLL in elderly The Oncology Report In the phase III CLL11 study, median progression-free survival (PFS) was 23 months for patients treated with a combination of obinutuzumab (GA101) and chlorambucil (Leukeran), 15.7 months for those treated with rituximab (MabThera) and chlorambucil, ... |
